Predictors of Paroxysmal Atrial Fibrillation in Patients With a Cryptogenic Stroke: Selecting Patients for Long-Term Rhythm Monitoring.

atrial cardiomyopathy atrial fibrillation cryptogenic stroke implantable cardiac monitor long-term rhythm monitoring risk stratification

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
03 Jul 2024
Historique:
received: 03 06 2024
revised: 21 06 2024
accepted: 01 07 2024
medline: 6 7 2024
pubmed: 6 7 2024
entrez: 5 7 2024
Statut: aheadofprint

Résumé

After a cryptogenic stroke, patients will often require prolonged cardiac monitoring; however, the subset of patients who would benefit from long-term rhythm monitoring is not clearly defined. Using significant predictors of AF using age, sex, comorbidities, baseline 12-lead electrocardiogram, short term rhythm monitoring and echocardiogram data, we created a risk score and compared it to previously published risk scores. Patients admitted to Montefiore Medical Center between May 2017 and June 2022 with a primary diagnosis of cryptogenic stroke or TIA who underwent long-term rhythm monitoring with an implantable cardiac monitor were retrospectively analyzed. Variables positively associated with a diagnosis of clinically significant atrial fibrillation include age (p < 0.001), race (p = 0.022), diabetes status (p = 0.026), and COPD status (p = 0.012), the presence of atrial runs (p = 0.003), the number of atrial runs per 24 hours (p < 0.001), the total number of atrial run beats per 24 hours (p < 0.001) and the number of beats in the longest atrial run (p < 0.001), LA enlargement (p = 0.007) and at least mild mitral regurgitation (p = 0.009). We created a risk stratification score for our population, termed the "ACL score." The ACL score demonstrated superiority to the CHA2DS2-VASc score and comparability to the C2HEST score for predicting device-detected AF. The ACL score enables clinicians to better predict which patients are more likely to be diagnosed with device-detected AF after a cryptogenic stroke.

Sections du résumé

BACKGROUND BACKGROUND
After a cryptogenic stroke, patients will often require prolonged cardiac monitoring; however, the subset of patients who would benefit from long-term rhythm monitoring is not clearly defined.
OBJECTIVE OBJECTIVE
Using significant predictors of AF using age, sex, comorbidities, baseline 12-lead electrocardiogram, short term rhythm monitoring and echocardiogram data, we created a risk score and compared it to previously published risk scores.
METHODS METHODS
Patients admitted to Montefiore Medical Center between May 2017 and June 2022 with a primary diagnosis of cryptogenic stroke or TIA who underwent long-term rhythm monitoring with an implantable cardiac monitor were retrospectively analyzed.
RESULTS RESULTS
Variables positively associated with a diagnosis of clinically significant atrial fibrillation include age (p < 0.001), race (p = 0.022), diabetes status (p = 0.026), and COPD status (p = 0.012), the presence of atrial runs (p = 0.003), the number of atrial runs per 24 hours (p < 0.001), the total number of atrial run beats per 24 hours (p < 0.001) and the number of beats in the longest atrial run (p < 0.001), LA enlargement (p = 0.007) and at least mild mitral regurgitation (p = 0.009). We created a risk stratification score for our population, termed the "ACL score." The ACL score demonstrated superiority to the CHA2DS2-VASc score and comparability to the C2HEST score for predicting device-detected AF.
CONCLUSION CONCLUSIONS
The ACL score enables clinicians to better predict which patients are more likely to be diagnosed with device-detected AF after a cryptogenic stroke.

Identifiants

pubmed: 38969049
pii: S1547-5271(24)02875-3
doi: 10.1016/j.hrthm.2024.07.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Samuel J Apple (SJ)

New York City Health and Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: SApple93@gmail.com.

Matthew Parker (M)

New York City Health and Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

David Flomenbaum (D)

Montefiore Medical Center, Bronx, New York, USA.

Shalom M Rosenbaum (SM)

New York City Health and Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Joshua Borck (J)

Montefiore Medical Center, Bronx, New York, USA.

Adrian Choppa (A)

Montefiore Medical Center, Bronx, New York, USA.

Pawel Borkowski (P)

New York City Health and Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Vikyath Satish (V)

New York City Health and Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Majd Al Deen Alhuarrat (M)

New York City Health and Hospitals/Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

John Fisher (J)

Montefiore Medical Center, Bronx, New York, USA.

Luigi Di Biase (L)

Montefiore Medical Center, Bronx, New York, USA.

Andrew Krumerman (A)

Northwell Health, Northern Westchester Hospital, Mount Kisco, NY, USA.

Kevin J Ferrick (KJ)

Montefiore Medical Center, Bronx, New York, USA.

Classifications MeSH